| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0264-410X(97)00254-5 |
| P698 | PubMed publication ID | 9562690 |
| P50 | author | Moncef Slaoui | Q88965331 |
| P2093 | author name string | P Van Damme | |
| A Meheus | |||
| G Leroux-Roels | |||
| I Desombere | |||
| A Safary | |||
| C Mathei | |||
| S Thoelen | |||
| P Vandepapeliere | |||
| P2860 | cites work | Adjuvants for human vaccines--current status, problems and future prospects | Q34373525 |
| Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination | Q34403593 | ||
| Factors influencing the immune response to hepatitis B vaccine, booster dose guidelines, and vaccine protocol recommendations | Q38256760 | ||
| Recombinant versus plasma-derived hepatitis B vaccines: issues of safety, immunogenicity and cost-effectiveness | Q39488403 | ||
| A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report | Q44266138 | ||
| Protective efficacy of a recombinant deoxyribonucleic acid hepatitis B vaccine in institutionalized mentally handicapped clients. | Q50556382 | ||
| A prospective study of in vitro anti-HBs producing B cells (spot-ELISA) following primary and supplementary vaccination with a recombinant hepatitis B vaccine in insulin dependent diabetic patients and matched controls | Q52083181 | ||
| Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men | Q69997141 | ||
| Hepatitis B vaccine boosting: the debate continues | Q72172533 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hepatitis B | Q6853 |
| Hepatitis B vaccine | Q117749 | ||
| vaccine | Q134808 | ||
| immunologic adjuvant | Q967453 | ||
| P1104 | number of pages | 7 | |
| P304 | page(s) | 708-714 | |
| P577 | publication date | 1998-04-01 | |
| P1433 | published in | Vaccine | Q7907941 |
| P1476 | title | Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system | |
| P478 | volume | 16 |
| Q80049574 | A controlled clinical trial comparing the safety and immunogenicity of a new adjuvanted hepatitis B vaccine with a standard hepatitis B vaccine |
| Q38872315 | A hepatitis B vaccine formulated with a novel adjuvant system |
| Q36452968 | A new synthetic TLR4 agonist, GLA, allows dendritic cells targeted with antigen to elicit Th1 T-cell immunity in vivo |
| Q34189153 | A prophylactic hepatitis B vaccine with a novel adjuvant system |
| Q35874598 | A review of licensed viral vaccines, some of their safety concerns, and the advances in the development of investigational viral vaccines |
| Q43650387 | A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections |
| Q34173229 | Adjuvant activity of emulsan, a secreted lipopolysaccharide from acinetobacter calcoaceticus |
| Q33591055 | Adjuvant activity of monophosphoryl lipid A for nasal and oral immunization with soluble or liposome-associated antigen |
| Q33764666 | Advances in vaccine adjuvants |
| Q44574133 | Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. |
| Q41586691 | Assessment of immunogenicity and protective efficacy of Microsporum canis secreted components coupled to monophosphoryl lipid-A adjuvant in a vaccine study using guinea pigs |
| Q81205526 | CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study |
| Q73502903 | CpG DNA induces stronger immune responses with less toxicity than other adjuvants |
| Q35166828 | CpG motifs: the active ingredient in bacterial extracts? |
| Q40796063 | Effect of adjuvant composition on immune response to a multiple antigen peptide (MAP) containing a protective epitope from Neisseria meningitidis class 1 porin. |
| Q59692337 | Effect of monophosphoryl lipid A (MPL) on T-helper cells when administered as an adjuvant with pneumocococcal-CRM197 conjugate vaccine in healthy toddlers |
| Q39585262 | Efficacy and safety studies of a recombinant chimeric respiratory syncytial virus FG glycoprotein vaccine in cotton rats |
| Q45740854 | Enhancement of the immune response to hepatitis B virus vaccine by antigen specific IgM. |
| Q74092600 | Hepatitis B surface antigen (HBsAg) derived from yeast cells (Hansenula polymorpha) used to establish an influence of antigenic subtype (adw2, adr, ayw3) in measuring the immune response after vaccination |
| Q49045963 | Immune response of HLA DQ2 positive subjects, vaccinated with HBsAg/AS04, a hepatitis B vaccine with a novel adjuvant |
| Q34128082 | Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis |
| Q30373740 | Incorporation of LpxL1, a detoxified lipopolysaccharide adjuvant, in influenza H5N1 virosomes increases vaccine immunogenicity. |
| Q90169705 | Induction of protective anti-plague immune responses by self-adjuvanting bionanoparticles derived from the engineered Yersinia pestis |
| Q34701875 | Inefficient TLR4/MD-2 heterotetramerization by monophosphoryl lipid A |
| Q34104222 | Lifelong protection against hepatitis B: the role of vaccine immunogenicity in immune memory |
| Q34164779 | Lipopolysaccharide potentiates effector T cell accumulation into nonlymphoid tissues through TRIF |
| Q34126807 | Mechanisms of monophosphoryl lipid A augmentation of host responses to recombinant HagB from Porphyromonas gingivalis |
| Q35131619 | Microbial products in allergy prevention and therapy. |
| Q45738401 | Monophosphoryl lipid A adjuvant reverses a principal histologic parameter of formalin-inactivated respiratory syncytial virus vaccine-induced disease |
| Q30357932 | New vaccines against influenza virus. |
| Q34999938 | Novel drugs targeting Toll-like receptors for antiviral therapy |
| Q34806001 | Novel vaccine strategies |
| Q37439440 | Optimized subunit vaccine protects against experimental leishmaniasis |
| Q34122078 | Oral vaccination with subunit vaccines protects animals against aerosol infection with Mycobacterium tuberculosis |
| Q89878357 | Protection and Safety Evaluation of Live Constructions Derived from the Pgm- and pPCP1- Yersinia pestis Strain |
| Q53994979 | Quantitation of Monophosphorylated Lipid A in the Oil-in-Water Adjuvant Delivery Systems Using Transesterification and GC-MS. |
| Q34756188 | Recent advances in vaccine adjuvants |
| Q34376294 | Recent developments in adjuvants for vaccines against infectious diseases |
| Q35109126 | Recombinant hepatitis B vaccine (Engerix-B): a review of its immunogenicity and protective efficacy against hepatitis B. |
| Q34001129 | Resistance to Coccidioides immitis in mice after immunization with recombinant protein or a DNA vaccine of a proline-rich antigen |
| Q61617993 | Safety and immunogenicity profile of an experimental hepatitis B vaccine adjuvanted with AS04 |
| Q39412381 | Safety evaluation of a glutaraldehyde modified tyrosine adsorbed housedust mite extract containing monophosphoryl lipid A (MPL) adjuvant: a new allergy vaccine for dust mite allergy |
| Q35991169 | Short-Fragment DNA Residue from Vaccine Purification Processes Promotes Immune Response to the New Inactivated EV71 Vaccine by Upregulating TLR9 mRNA |
| Q37710808 | Systems Pharmacology-based strategy to screen new adjuvant for hepatitis B vaccine from Traditional Chinese Medicine Ophiocordyceps sinensis |
| Q37256021 | T cell responses to hepatitis B surface antigen are detectable in non-vaccinated individuals |
| Q34400322 | TLR-based immune adjuvants. |
| Q41963209 | The PorB porin from commensal Neisseria lactamica induces Th1 and Th2 immune responses to ovalbumin in mice and is a potential immune adjuvant. |
| Q35191988 | The Toll-like receptor 4 agonist monophosphoryl lipid a augments innate host resistance to systemic bacterial infection |
| Q80843163 | The clinical grade maturation cocktail monophosphoryl lipid A plus IFNgamma generates monocyte-derived dendritic cells with the capacity to migrate and induce Th1 polarization |
| Q28218447 | The global impact of vaccines containing aluminium adjuvants |
| Q78424586 | The immunogenicity and reactogenicity profile of a candidate hepatitis B vaccine in an adult vaccine non-responder population |
| Q37073999 | Toll-Like Receptor 4 Agonistic Antibody Promotes Host Defense against Chronic Pseudomonas aeruginosa Lung Infection in Mice. |
| Q79897713 | Toll-free vaccines? |
| Q34324978 | Towards the rational design of Th1 adjuvants |
| Q36547133 | Understanding how lipopolysaccharide impacts CD4 T-cell immunity |
| Q40718609 | Vaccination against hepatitis B in health care workers |
| Q38806558 | Vaccine technologies: From whole organisms to rationally designed protein assemblies |
| Q73747937 | Vaccines for transplant recipients |
| Q35131573 | Vaccines for viral diseases with dermatologic manifestations |
| Q47411366 | Very small size proteoliposomes derived from Neisseria meningitidis: an effective adjuvant for Th1 induction and dendritic cell activation |
| Q41630140 | mTOR regulates TLR-induced c-fos and Th1 responses to HBV and HCV vaccines |
Search more.